Prospective study of 174 de novo acute myelogenous leukemias according to the WHO classification: Subtypes, cytogenetic features and FLT3 mutations

European Journal of Haematology

Volumn 77, Issue 1, 2006, Pages 35-45

  Bao, Liming ^a,b   Wang, Xiaoqin ^b,c   Ryder, John ^d   Ji, Meirong ^c   Chen, Yan ^b   Chen, Hui ^b   Sun, Hengjuan ^b   Yang, Yongchen ^b   Du, Xinyu ^e   Kerzic, Patrick ^d   Gross, Sherilyn A ^d   Yao, Lihong ^b   Lv, Ling ^c   Fu, Hua ^b   Lin, Guowei ^c   Irons, Richard D ^b,d  

^a UNIVERSITY OF CINCINNATI   (United States)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d UNIVERSITY OF COLORADO   (United States)

^e SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Acute myeloid leukemia; Cytogenetics; FAB; FLT3; WHO

Indexed keywords

FLT3 LIGAND; PROTEIN TYROSINE KINASE;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CONTROLLED STUDY; CYTOGENETICS; FEMALE; GENE MUTATION; HUMAN; INCIDENCE; LEUKOCYTOSIS; LITERATURE; MAJOR CLINICAL STUDY; MALE; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CLASSIFICATION; CYTOGENETIC ANALYSIS; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKOCYTOSIS; MALE; MIDDLE AGED; MUTATION; PROSPECTIVE STUDIES; WORLD HEALTH ORGANIZATION;

EID: 33745049892     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2006.00660.x     Document Type: Article

References (39)

1. Bennett JM Catovsky D Daniel MT Flandrin G Galton DA Gralnick HR Sultan C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976 33 : 451 458.
2. Jaffe E Harris N Stein H Vardiman J. Pathology and Genetics of Tumours of Haematoloietic and Lymphoid Tissues. Lyon, France : IARC Press, 2001.
3. Vardiman JW Harris NL Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002 100 : 2292 2302.
4. Schoch C Schnittger S Klaus M Kern W Hiddemann W Haferlach T. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 2003 102 : 2395 2402.
5. Arber DA Stein AS Carter NH Ikle D Forman SJ Slovak ML. Prognostic impact of acute myeloid leukemia classification. Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival. Am J Clin Pathol 2003 119 : 672 680.
6. Goumakou E Papadhimitriou SI Kritikou-Griva E Marinakis T Paterakis G Davea A Levivada A Galanopoulos A Anagnostopoulos NI. The FAB and WHO classification in AML: an analysis from the application in 150 cases. Haema 2005 8 : 465 472.
7. Caligiuri MA Strout MP Gilliland DG. Molecular biology of acute myeloid leukemia. Semin Oncol 1997 24 : 32 44.
8. Dowing JR. Childhood Leukemias. Cambridge, UK : Cambridge University Press, 1999 : 219 355.
9. Levis M Small D. FLT3: ITDoes matter in leukemia. Leukemia 2003 17 : 1738 1752.
10. Nakao M Yokota S Iwai T Kaneko H Horiike S Kashima K Sonoda Y Fujimoto T Misawa S. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996 10 : 1911 1918.
11. Rombouts WJ Blokland I Lowenberg B Ploemacher RE. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia 2000 14 : 675 683.
12. Abu-Duhier FM Goodeve AC Wilson GA Gari MA Peake IR Rees DC Vandenberghe EA Winship PR Reilly JT. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol 2000 111 : 190 195.
13. Kottaridis PD Gale RE Frew ME et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001 98 : 1752 1759.
14. Frohling S Schlenk RF Breitruck J Benner A Kreitmeier S Tobis K Dohner H Dohner K. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002 100 : 4372 4380.
15. Chillon MC Fernandez C Garcia-Sanz R Balanzategui A Ramos F Fernandez-Calvo J Gonzalez M Miguel JF. FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor. Hematol J 2004 5 : 239 246.
16. Mitelman F. An International System for Human Cytogenetic Nomenclature. New York : Karger, 1995.
17. Raimondi SC Chang MN Ravindranath Y Behm FG Gresik MV Steuber CP Weinstein HJ Carroll AJ. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood 1999 94 : 3707 3716.
18. Slovak ML Kopecky KJ Cassileth PA et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000 96 : 4075 4083.
19. Grimwade D Walker H Oliver F et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998 92 : 2322 2333.
20. Meshinchi S Woods WG Stirewalt DL Sweetser DA Buckley JD Tjoa TK Bernstein ID Radich JP. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001 97 : 89 94.
21. Yamamoto Y Kiyoi H Nakano Y et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001 97 : 2434 2439.
22. Rowe D Cotterill SJ Ross FM et al. Cytogenetically cryptic AML1-ETO and CBF beta-MYH11 gene rearrangements: incidence in 412 cases of acute myeloid leukaemia. Br J Haematol 2000 111 : 1051 1056.
23. Schiffer CA Lee EJ Tomiyasu T Wiernik PH Testa JR. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 1989 73 : 263 270.
24. Sole F Caballin MR Coll MD Woessner S Besses C Sans-Sabrafen J Egozcue J. Cytogenetic studies in acute nonlymphocytic leukemia. Cancer Genet Cytogenet 1992 60 : 117 124.
25. Palka G Calabrese G Fioritoni G Stuppia L Guanciali Franchi P Marino M Antonucci A Spadano A Torlontano G. Cytogenetic survey of 80 patients with acute nonlymphocytic leukemia. Cancer Genet Cytogenet 1992 59 : 45 50.
26. Tien HF Wang CH Lin MT Lee FY Liu MC Chuang SM Chen YC Shen MC Lin KH Lin DT. Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia. A study of 235 Chinese patients in Taiwan. Cancer Genet Cytogenet 1995 84 : 60 68.
27. Nakase K Bradstock K Sartor M Gottlieb D Byth K Kita K Shiku H Kamada N. Geographic heterogeneity of cellular characteristics of acute myeloid leukemia: a comparative study of Australian and Japanese adult cases. Leukemia 2000 14 : 163 168.
28. Anderson JR Armitage JO Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998 9 : 717 720.
29. Beyer V Castagne C Muhlematter D et al. Systematic screening at diagnosis of -5/del(5)(q31), -7, or chromosome 8 aneuploidy by interphase fluorescence in situ hybridization in 110 acute myelocytic leukemia and high-risk myelodysplastic syndrome patients: concordances and discrepancies with conventional cytogenetics. Cancer Genet Cytogenet 2004 152 : 29 41.
30. Heim S Mitelman F. Cancer Cytogenetics, 2nd edn. New York : Wiley-Liss, 1995.
31. Byrd JC Mrozek K Dodge RK et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002 100 : 4325 4336.
32. Peniket AJ. Del(9q) acute myeloid leukaemia: clinical and cytological characteristics and prognostic implications. Br J Haematol 2005 130 : 969. author reply 969.
33. Peniket A Wainscoat J Side L et al. Del (9q) AML: clinical and cytological characteristics and prognostic implications. Br J Haematol 2005 129 : 210 220.
34. Rege K Swansbury GJ Atra AA et al. Disease features in acute myeloid leukemia with t(8;21)(q22;q22). Influence of age, secondary karyotype abnormalities, CD19 status, and extramedullary leukemia on survival. Leuk Lymphoma 2000 40 : 67 77.
35. Au WY Fung A Chim CS Lie AK Liang R Ma ES Chan CH Wong KF Kwong YL. FLT-3 aberrations in acute promyelocytic leukaemia: clinicopathological associations and prognostic impact. Br J Haematol 2004 125 : 463 469.
36. Kiyoi H Naoe T Yokota S et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 1997 11 : 1447 1452.
37. Andersson A Johansson B Lassen C Mitelman F Billstrom R Fioretos T. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients. Eur J Haematol 2004 72 : 307 313.
38. Shih LY Kuo MC Liang DC Huang CF Lin TL Wu JH Wang PN Dunn P Lai CL. Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia. Cancer 2003 98 : 1206 1216.
39. Yokota S Kiyoi H Nakao M et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997 11 : 1605 1609.